

(54) Title of the invention : Compositions Comprising Phloretin as Adjuvant Therapy

(51) International classification :A61P0025080000, A61P0035000000, A61P0025280000, A61K0008350000, A61P0031060000

(86) International Application No :NA  
Filing Date :NA

(87) International Publication No : NA

(61) Patent of Addition to Application Number :NA  
Filing Date :NA

(62) Divisional to Application Number :NA  
Filing Date :NA

(71)Name of Applicant :  
**1)KALPESH RAMDAS PATIL**  
Address of Applicant :Department of Pharmacology, R. C. Patel Institute of Pharmaceutical Education & Research, Karvand Naka, Shirpur-425405, Dist - Dhule (Maharashtra), INDIA. -----

Name of Applicant : NA  
Address of Applicant : NA

(72)Name of Inventor :  
**1)SHITALKUMAR PUKHARAJ ZAMBAD**  
Address of Applicant :Department of Pharmacology, R. C. Patel Institute of Pharmaceutical Education & Research, Karvand Naka, Shirpur-425405, Dist - Dhule (Maharashtra), INDIA. Shirpur -----

**2)KALPESH RAMDAS PATIL**  
Address of Applicant :Department of Pharmacology, R. C. Patel Institute of Pharmaceutical Education & Research, Karvand Naka, Shirpur-425405, Dist - Dhule (Maharashtra), INDIA. -----

**3)SHIVAM KAILAS CHAUDHARI**  
Address of Applicant :AT- BHOKARI, POST- KERHALE, TAL. -RAVER, DIST.- JALGAON, BHOKARI MAHARASHTRA, INDIA -425508. -----

**4)CHANDRAKANTSING VIJAYSING PARDESHI**  
Address of Applicant :DEPARTMENT OF PHARMACEUTICS, R. C. PATEL INSTITUTE OF PHARMACEUTICAL EDUCATION & RESEARCH, KARVAND NAKA, SHIRPUR, DIST. DHULE, MAHARASHTRA, INDIA-425405. -----

**5)PITAMBAR NILKANTH DIGHORE**  
Address of Applicant :7, MAHESH NAGAR, RADHA HOSPITAL, NEAR BUS STAND, SHIRPUR, DIST. DHULE, MAHARASHTRA, INDIA-425405. -----

(57) Abstract :  
ABSTRACT COMPOSITIONS COMPRISING PHLORETIN AS ADJUVANT THERAPY The present invention provides phloretin (PHL) as an adjuvant therapy for enhancing the efficacy and safety of standard treatments for cancer, tuberculosis, epilepsy, and neurodegeneration. Through preclinical studies, phloretin demonstrated significant protective effects against drug-induced toxicities, particularly nephrotoxicity associated with cisplatin and hepatotoxicity from isoniazid and rifampicin. The findings indicate that phloretin not only enhances the therapeutic outcomes of these standard therapies but also reduces their adverse effects, thereby improving patient compliance and quality of life. By leveraging phloretin’s antioxidant and anti-inflammatory properties, this invention presents a promising approach to mitigate treatment-related complications and optimize therapeutic strategies across various medical conditions. (Figure-1 shall be the abstract figure)




Fig. 1.

No. of Pages : 32 No. of Claims : 12